Literature DB >> 14742532

Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Philippe Lehours1, Armelle Ménard, Sandrine Dupouy, Bernard Bergey, Fréderique Richy, Frank Zerbib, Agnès Ruskoné-Fourmestraux, Jean Charles Delchier, Francis Mégraud.   

Abstract

Helicobacter pylori has been associated with the development of two malignant diseases: gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although the cag pathogenicity island, especially the cagA gene, has been linked with adenocarcinoma, few data concerning H. pylori pathogenic factors involved in low-grade gastric MALT lymphoma are available. The goal of this study was to analyze the prevalence of and correlation between genes coding for seven H. pylori virulence factors (cagA, cagE, vacA, iceA, babA, hopQ, and oipA) and two novel adhesins (sabA and hopZ) by comparing a collection of 43 H. pylori strains isolated from patients with low-grade gastric MALT lymphoma to 39 strains isolated from age-matched patients with gastritis only. Our results show that taken individually, none of the nine genes tested can be considered associated with MALT strains and allow us to conclude that MALT pathogenesis is not linked with more proinflammatory H. pylori strains. We demonstrated that in patients infected with strains harboring the iceA1 allele, sabA functional status, and hopZ "off" status, the odds of developing a MALT lymphoma were 10 times higher. However, the low prevalence of such strains (10 of 43 MALT strains) renders this triple association a low-sensitivity marker for MALT strains. Our data confirmed that H. pylori virulence factors are correlated with one another. If the involvement of H. pylori in MALT lymphoma is well established, the pathomechanism by which gastric lymphoma occurs remains to be identified.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742532      PMCID: PMC321584          DOI: 10.1128/IAI.72.2.880-888.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

Review 1.  Helicobacter pylori and duodenal ulcer. Evidence suggesting causation.

Authors:  F Mégraud; H Lamouliatte
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

2.  Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori.

Authors:  B Peck; M Ortkamp; K D Diehl; E Hundt; B Knapp
Journal:  Nucleic Acids Res       Date:  1999-08-15       Impact factor: 16.971

3.  The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response.

Authors:  Roland Rad; Markus Gerhard; Roland Lang; Martin Schöniger; Thomas Rösch; Wolfgang Schepp; Ingrid Becker; Hermann Wagner; Christian Prinz
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

4.  Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks.

Authors:  P Correa; J Fox; E Fontham; B Ruiz; Y P Lin; D Zavala; N Taylor; D Mackinley; E de Lima; H Portilla
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

5.  Two different families of hopQ alleles in Helicobacter pylori.

Authors:  Ping Cao; Timothy L Cover
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

6.  Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma?

Authors:  Philippe Lehours; Agnès Ruskone-Fourmestraux; Anne Lavergne; Franck Cantet; Francis Mégraud
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

7.  Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation.

Authors:  Jafar Mahdavi; Berit Sondén; Marina Hurtig; Farzad O Olfat; Lina Forsberg; Niamh Roche; Jonas Angstrom; Thomas Larsson; Susann Teneberg; Karl-Anders Karlsson; Siiri Altraja; Torkel Wadström; Dangeruta Kersulyte; Douglas E Berg; Andre Dubois; Christoffer Petersson; Karl-Eric Magnusson; Thomas Norberg; Frank Lindh; Bertil B Lundskog; Anna Arnqvist; Lennart Hammarström; Thomas Borén
Journal:  Science       Date:  2002-07-26       Impact factor: 47.728

8.  Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production.

Authors:  Yoshio Yamaoka; Shogo Kikuchi; Hala M T el-Zimaity; Oscar Gutierrez; Michael S Osato; David Y Graham
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

9.  Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production.

Authors:  M K Tummuru; T L Cover; M J Blaser
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Determination of Helicobacter pylori vacA allelic types by single-step multiplex PCR.

Authors:  S A Chisholm; E L Teare; B Patel; R J Owen
Journal:  Lett Appl Microbiol       Date:  2002       Impact factor: 2.858

View more
  46 in total

1.  Non-invasive genotyping of Helicobacter pylori cagA, vacA, and hopQ from asymptomatic children.

Authors:  Liviu A Sicinschi; Pelayo Correa; Luis E Bravo; Richard M Peek; Keith T Wilson; John T Loh; Maria C Yepez; Benjamin D Gold; Dexter T Thompson; Timothy L Cover; Barbara G Schneider
Journal:  Helicobacter       Date:  2012-04       Impact factor: 5.753

2.  Helicobacter pylori outer membrane proteins and gastroduodenal disease.

Authors:  Y Yamaoka; O Ojo; S Fujimoto; S Odenbreit; R Haas; O Gutierrez; H M T El-Zimaity; R Reddy; A Arnqvist; D Y Graham
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

3.  Identification of markers for Helicobacter pylori strains isolated from children with peptic ulcer disease by suppressive subtractive hybridization.

Authors:  Mónica Oleastro; Lurdes Monteiro; Philippe Lehours; Francis Mégraud; Armelle Ménard
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Clinical relevance of cagL gene and virulence genotypes with disease outcomes in a Helicobacter pylori infected population from Iran.

Authors:  Abbas Yadegar; Ashraf Mohabati Mobarez; Masoud Alebouyeh; Tabassom Mirzaei; Terry Kwok; Mohammad Reza Zali
Journal:  World J Microbiol Biotechnol       Date:  2014-05-23       Impact factor: 3.312

5.  [Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy].

Authors:  M Eck; W Fischbach
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

6.  Prevalence of virulence-associated genotypes of Helicobacter pylori and correlation with severity of gastric pathology in patients from western Sicily, Italy.

Authors:  A Chiarini; C Calà; C Bonura; A Gullo; G Giuliana; S Peralta; F D'Arpa; A Giammanco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-29       Impact factor: 3.267

Review 7.  Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis.

Authors:  Yoshio Yamaoka
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

8.  Identification of a genetic marker of Helicobacter pylori strains involved in gastric extranodal marginal zone B cell lymphoma of the MALT-type.

Authors:  P Lehours; S Dupouy; B Bergey; A Ruskoné-Foumestraux; J C Delchier; R Rad; F Richy; J Tankovic; F Zerbib; F Mégraud; A Ménard
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  Is there a link between the lipopolysaccharide of Helicobacter pylori gastric MALT lymphoma associated strains and lymphoma pathogenesis?

Authors:  Philippe Lehours; Zongli Zheng; Anna Skoglund; Francis Mégraud; Lars Engstrand
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

10.  Expression of the Helicobacter pylori adhesin SabA is controlled via phase variation and the ArsRS signal transduction system.

Authors:  Andrew C Goodwin; Daniel M Weinberger; Christopher B Ford; Jessica C Nelson; Jonathan D Snider; Joshua D Hall; Catharine I Paules; Richard M Peek; Mark H Forsyth
Journal:  Microbiology       Date:  2008-08       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.